Skip to main content
SpringerLink
Log in

Gleevec linked to LVEF reduction and CHF

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Novartis Pharmaceuticals Canada Inc.Health Canada endorsed important safety information on GLEEVEC (imatinib mesylate). Internet Document: [3 pages], 21 Sep 2006. Available from: URL: http://www.hc-sc.gc.ca

  2. Health Canada.Recent safety information regarding reports of heart problems in patients using GLEEVEC* (imatinib mesylate). Media Release: 21 Sep 2006. Available from: URL: http://www.hc-sc.gc.ca

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gleevec linked to LVEF reduction and CHF. React. Wkly. 1122, 3 (2006). https://doi.org/10.2165/00128415-200611220-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200611220-00005

Keywords

Search

Navigation